10x Genomics, Inc.
Rank #115StartupTXG · Nasdaq · Healthcare
10x Genomics, Inc. (TXG) — Rank #115 by gross profitability (GP/assets 0.43) · ROE -5.3% · Piotroski F-Score N/A.
As-of 2026-09-28 · CIK 0001770787 · all metrics point-in-time as of the filing date.
About
10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific.
Show moreShow less
The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits. It also provides Visium platform, a spatial analysis platform that uses high density DNA arrays to encode the physical location of biological analytes within a sample. This platform includes HD WT panel gene expression, and HD 3' gene expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides. In addition, the company offers Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section without the need for conventional sequencing; and slides and reagents. Further, it provides various software products comprising Cell Ranger, a scRNA-seq processing pipeline in scientific literature; Loupe Browser, which enables intuitive single-cell, spatial, and multiomic data visualization; and Xenium Explorer that enables intuitive in situ data visualization, which allows researchers to explore subcellular gene expression, spatial organization, and tissue-scale patterns. The company serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc.
was incorporated in 2012 and is headquartered in Pleasanton, California.
- Industry
- Medical Devices
- Sector
- Healthcare
- State
- DE
- Filer Category
- Large accelerated filer
- Fiscal Year End
- December 31
- Website
- 10xgenomics.com
Financials
Each fiscal year is read as-of that year’s own 10-K filing, so nothing restated after the fact leaks backwards. Line items this filer never tagged are omitted. Hover or tap a badge for the diagnostic behind it.
| Fiscal year end | 2025-12-31filed 2026-02-13 | 2024-12-31filed 2025-02-13 | 2023-12-31filed 2024-02-15 | 2022-12-31filed 2023-02-16 |
|---|---|---|---|---|
| Assets | ||||
| Cash & equivalents | 474.0 | 344.1 | 359.3 | 219.7 |
| Short-term investments | 49.4 | 49.3 | 29.4 | 210.2 |
| Accounts receivable | 47.0 | 87.9 | 114.8 | 104.2 |
| Inventory | 56.3 | 83.1 | 73.7 | 81.6 |
| Total current assets | 684.5 | 584.4 | 596.0 | 635.0 |
| Property, plant & equipment, net | 226.7 | 252.6 | 279.6 | 289.3 |
| Goodwill | 4.5 | 4.5 | 4.5 | 4.5 |
| Intangible assets (excl. goodwill) | 62.3 | 15.7 | 16.6 | 22.9 |
| Total assets | 1,041.4 | 918.6 | 965.1 | 1,029.0 |
| Liabilities | ||||
| Accounts payable | 12.7 | 12.9 | 15.7 | 21.6 |
| Deferred revenue | 23.9 | 20.7 | 13.2 | 7.9 |
| Total current liabilities | 153.5 | 117.6 | 127.2 | 131.0 |
| Total debt | — | — | — | — |
| Total liabilities | 245.0 | 208.5 | 224.1 | 223.2 |
| Equity | ||||
| Retained earnings | (1,510.6) | (1,467.0) | (1,284.4) | (1,029.3) |
| Total shareholders' equity | 796.3 | 710.1 | 741.0 | 805.7 |
Figures are as originally filed with the SEC (point-in-time), not restated, so they can differ slightly from sites that show later-restated numbers. Why point-in-time?